SR
GH icon

Syntax Research’s Guardant Health GH Stock Holding History

Syntax Research’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200
Closed -$10.4K – 178
2025
Q2 		$10.4K Hold
200
– – 0.01% 136
2025
Q1 		$8.52K Hold
200
– – 0.01% 142
2024
Q4 		$6.11K Hold
200
– – ﹤0.01% 163
2024
Q3 		$4.59K Hold
200
– – ﹤0.01% 172
2024
Q2 		$5.78K Hold
200
– – ﹤0.01% 150
2024
Q1 		$4.13K Hold
200
– – ﹤0.01% 159
2023
Q4 		$5.41K Hold
200
– – ﹤0.01% 157
2023
Q3 		$5.93K Buy
+200
New +$7.03K ﹤0.01% 155

Other funds holding GH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Syntax Research's GH Position: Q3 2025 in Review

Syntax Research sold out of Guardant Health (GH) in Q3 2025, closing a stake of 200 shares — an estimated $10.4K sold.

Syntax Research first reported a position in GH in Q3 2023 and held it in 8 quarters. The position peaked at $10.4K in Q2 2025. 395 funds tracked by Wall St. Rank hold GH as of Q3 2025.

  • Syntax Research reported no remaining Guardant Health position as of Q3 2025 after selling out during the quarter.
  • Syntax Research sold 200 Guardant Health shares in Q3 2025, an estimated $10.4K.
  • Syntax Research first reported a position in Guardant Health in Q3 2023 and held it in 8 quarters.
  • Syntax Research's Guardant Health position peaked at $10.4K in Q2 2025.
  • 395 funds tracked by Wall St. Rank held Guardant Health as of Q3 2025.

Based on Syntax Research's 13F filing for Q3 2025, filed 4 Nov 2025.